Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Assembly Biosciences, Inc. (NASDAQ:ASMB) has been given an average rating of “Moderate Buy” by the seven research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $41.75.

ASMB has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a report on Monday, December 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Wednesday, January 21st. Finally, Mizuho set a $40.00 price target on shares of Assembly Biosciences and gave the stock an “outperform” rating in a report on Thursday, November 20th.

Assembly Biosciences Trading Up 10.7%

Shares of ASMB opened at $28.75 on Friday. Assembly Biosciences has a 12 month low of $7.75 and a 12 month high of $39.71. The stock has a fifty day moving average price of $29.87 and a 200-day moving average price of $28.97. The firm has a market cap of $454.83 million, a PE ratio of -6.00 and a beta of 1.13.

Institutional Trading of Assembly Biosciences

Several large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE raised its stake in shares of Assembly Biosciences by 6,382.7% in the third quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 3,319 shares during the last quarter. Acadian Asset Management LLC raised its position in Assembly Biosciences by 42.1% during the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 6,823 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in Assembly Biosciences during the 4th quarter valued at approximately $228,000. Virtus Investment Advisers LLC purchased a new stake in shares of Assembly Biosciences in the 4th quarter valued at $251,000. Finally, Qube Research & Technologies Ltd purchased a new stake in shares of Assembly Biosciences in the 3rd quarter valued at $282,000. Hedge funds and other institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.